Resilient Collective Appoints Navin Puri as VP, Clinical Consultants

The Collective deepens its clinical expertise as Navin Puri takes the helm

LONDON, 10.04.2026 — Resilient Collective is proud to announce the appointment of Navin Puri as Vice President of Clinical Consultants. Navin is one of the Collective’s early experts and brings 25 years of experience in senior clinical management and leadership across the full breadth of life sciences.

In his new role, Navin will lead Resilient Collective's clinical consultants. He will bring together independent experts spanning the full clinical development lifecycle: from clinical operations and data management through to regulatory affairs, medical writing, safety and pharmacovigilance, and beyond.

“Navin has been thinking about how to grow and strengthen this Collective since the day he joined. That kind of ownership is rare. He has worked hard to bring our clinical consultants together as a coherent unit and has shown a genuine commitment to making RC something special for everyone in it. The clinical space is one of the most complex and demanding in biotech, and having someone with Navin's depth of experience, and his care for this community, leading the charge feels exactly right.” — Nia Emami, Founder & CEO, Resilient Collective

“Nia’s vision for the Resilient Collective immediately resonated with me - a refreshing approach to networking and collaboration that brings together independent experts who genuinely support one another while helping life sciences and healthcare companies tackle complex challenges. I’m honoured to be part of this exceptional community and to take on the role of Vice President of Clinical Consultants. I look forward to working with our consultants to help companies advance innovative therapies and treatments to improve patient care worldwide.” — Navin Puri, Vice President of Clinical Consultants, Resilient Collective

Navin brings the kind of depth that early-stage biotech companies rarely get access to. He has spent 25 years doing the work across the full clinical landscape, from early-stage biotechs and global pharma to CROs, medical devices, diagnostics, and public health. He returned to independent consulting in 2024 and has been part of the Collective since its early days.

From 2016 to 2024, he established and led an 8.5 year Functional Service Provider partnership with Roche, a cornerstone of his recent career. In that role, he drove global team buildouts, oversaw high-quality study execution across therapeutic areas, and delivered long-term strategic and operational leadership. It is the kind of engagement that demands both the big picture and the fine detail.

His expertise spans end-to-end operational delivery across all clinical phases and therapeutic areas, including companion diagnostics, precision medicine, targeted therapies, medical devices, and AI-enabled trials. He provides fractional leadership, GCP training, clinical quality and regulatory compliance assessments, audits, and inspection readiness. He also mentors undergraduate students, postdoctoral life sciences professionals, and CRAs.

Navin holds an MSc alongside an MRes in Leadership and Management, with a focus on life sciences. He has multiple clinical trial accreditations, and management qualifications from Harvard Business School and Henley Business School. His London-based consultancy serves clients across the US, EMEA, APAC, and beyond. Outside of his professional work, Navin has been a dedicated meditator and yoga practitioner since 2019. He is a Fellow of the Royal Asiatic Society and has a keen interest in Indian history.

About Resilient Collective

Resilient Collective is a pan-European biotech ecosystem catalyst. We are a curated community of 80+ independent experts spanning scientific, technical, and business functions across more than 10 countries. Every member has lived experience within the biotech industry, and joining the Collective means passing through a rigorous application and interview process. There is no cost for clients and no cost for experts. Companies access the Collective directly, engaging individual consultants or building a tailored team as their needs evolve. The flexibility and agility of working with true independents, with none of the overhead. Resilient Collective exists to drive biotech innovation forward, especially for early-stage companies that need world-class expertise without the barriers. Learn more at www.resilient-collective.com.